EUVIMEDAtrasti EUVIMED
Open access · CC BY 4.0

Exploring Causal Associations Between Plasma Metabolites and Autism Spectrum Disorder

Shangyun Shi iD, Ancha Baranova iD, Hongbao Cao iD, Fuquan Zhang iD

Alpha Psychiatry · 2025-11-14 · 26 (6)

DOI: 10.31083/ap48246 ↗

At a glance

Journal article in Alpha Psychiatry, published online on 2025-11-14. Written by Shangyun Shi and 3 co-authors. Institution: Department of Psychiatry, The Affiliated Brain Hospital of Nanjing Medical University, 210029 Nanjing, Jiangsu, China. Cited 2 times so far (Crossref); 61 references. The full text is freely available (open access, CC BY 4.0).

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Background

In autism spectrum disorder (ASD), the human plasma metabolome is altered but the causal relationship between the levels of metabolites and ASD is unclear. We aimed to assess bidirectional causal associations between plasma metabolites and ASD.

Methods

We investigated potential causal associations between the genetic variation contributing to the levels of metabolites and ASD via Mendelian randomization (MR) analyses. Genome-wide association study (GWAS) summary datasets were used in the study, including ASD (n = 46,350) and 871 plasma metabolite (n = 8299) datasets. We used druggability analysis to prioritize metabolites with therapeutic potential.

Results

Our MR analysis identified 32 plasma metabolites whose levels were protective against the risk of ASD, including 5 alpha-androstan-3 alpha, 17 beta-diol disulfate (odds ratio (OR): 0.94, 95% CI: 0.90–0.97) and 11beta-hydroxyetiocholanolone glucuronide (OR: 0.95, 95% CI: 0.92–0.98). Additionally, 12 metabolites were found to be positively associated with the risk of ASD, including indoleacetylglutamine (OR: 1.04, 95% CI: 1.01–1.08) and sphingomyelin (d18:1/24:1, d18:2/24:0) (OR: 1.06, 95% CI: 1.01–1.11). Some metabolites may be regulated through drug intervention, including sphingomyelin, chiro-inositol, carotene diol (1)/(2), and glycerol. Genetic variation contributing to ASD may increase the abundance of five metabolites, including deoxycholic acid glucuronide (OR: 1.18, 95% CI: 1.03–1.34); meanwhile, the abundance of 27 metabolites, including stearoyl choline (OR: 0.80, 95% CI: 0.69–0.92) may be causally reduced.

Conclusions

Our MR analysis uncovered bidirectional causal associations between certain plasma metabolites and ASD, suggesting that these metabolites could be biomarkers for ASD and paving the way for novel therapeutic targets in ASD phenotypes.

Subjects

Author keywords

Mendelian randomizationautism spectrum disordercausal associationplasma metabolite

Authors and institutions

  • Department of Psychiatry, The Affiliated Brain Hospital of Nanjing Medical University, 210029 Nanjing, Jiangsu, China.
  • School of Systems Biology, George Mason University, Fairfax, VA 22030, USA.
  • Research Centre for Medical Genetics, 115478 Moscow, Russia.
  • Institute of Neuropsychiatry, The Affiliated Brain Hospital of Nanjing Medical University, 210029 Nanjing, Jiangsu, China.

ORCID profiles: Shangyun Shi, Ancha Baranova, Hongbao Cao, Fuquan Zhang

Cite

APA

Shi, S., Baranova, A., Cao, H., & Zhang, F. (2025). Exploring Causal Associations Between Plasma Metabolites and Autism Spectrum Disorder. Alpha Psychiatry, 26(6). https://doi.org/10.31083/ap48246

Vancouver

Shi S, Baranova A, Cao H, Zhang F. Exploring Causal Associations Between Plasma Metabolites and Autism Spectrum Disorder. Alpha Psychiatry. 2025;26(6). doi:10.31083/ap48246

BibTeX
@article{Shi2025,
  author = {Shi, Shangyun and Baranova, Ancha and Cao, Hongbao and Zhang, Fuquan},
  title = {Exploring Causal Associations Between Plasma Metabolites and Autism Spectrum Disorder},
  journal = {Alpha Psychiatry},
  year = {2025},
  volume = {26},
  number = {6},
  doi = {10.31083/ap48246}
}
Start for free →